IL6 and inflammatory bowel disease: Next, BJ-3105 was evaluated for its inhibitory effect on TNF-α- and on IL-6-induced monocyte adhesion to HT-29 colonic epithelial cells, which is indicative of the early phase of colon inflammation and has been used to screen anti-IBD compounds [29,30].